BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioAtla, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026
- Market cap
- $2.18M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$40.18 (−96.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.18M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$31.45M
- EPS, diluted
- -$25.63
- Book value per share
- -$21.81
- Diluted shares
- 2M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$32.13M
Net income
-$31.45M
EPS, diluted
-$25.63
Reported periodTrailing twelve months